What Erleada treats: Main Uses and Benefits

Erleada is commonly used to help with the systemic management of prostate cancer across domains where additional symptomatic support is needed. The medication is relevant in conditions characterized by periods of heightened symptoms and disease activity. It is applied in addressing clinical stages that may be considered advanced.

Therapeutic Application and Supportive Benefit

The drug is relevant for managing symptoms associated with biochemical progression, which is applied in addressing the rapid increase of Prostate-Specific Antigen (PSA) levels, a major indicator of disease activity.

Erleada is generally applied in contexts involving advanced forms of the disease, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). This therapeutic application may be part of symptomatic management and helps patients cope more steadily with symptom fluctuations, contributing to improved comfort during symptomatic periods.

“It is commonly used to help with providing supportive relief against disease progression, which assists with maintaining functional stability for a longer period.”

This medication may assist with managing the risk of cancer spreading to other organs and bones. In situations where patients experience these markers, the treatment contributes to improved comfort and is relevant for managing symptoms that are more noticeable during high-risk disease states.

---

Quick Fact: Supportive Management for Disease Progression Erleada is applied in addressing the acceleration of the malignancy and provides supportive relief against disease progression in advanced prostate cancer.

Regulatory References

1. European Medicines Agency therapeutic overview

This section outlines the official population eligibility and non-eligibility rules for Erleada (Apalutamide), as defined by government regulatory documents.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations Allowed	Adult Males (18 years and older) indicated for nmCRPC or mCSPC.
Populations Contraindicated	Females, especially those who are or may become pregnant, due to the risk of fetal harm.
Age-Related Rules	Pediatric Population: Use is not established and has no relevant use.
	Older Adults (Geriatric): No dose adjustment is necessary based on age alone.
Organ Function Rules	Mild to Moderate Hepatic/Renal Impairment: No dose adjustment is necessary.
Pregnancy/Reproduction	Males with female partners of reproductive potential must use effective contraception during treatment and for 3 months after the last dose.

---

Eligibility-Context Constraints

Classification	Official Regulatory Wording
Not Recommended	Patients with severe hepatic impairment (Child-Pugh Class C) due to lack of data.
Caution Required	Patients with severe renal impairment should be treated with caution as the drug has not been studied in this population.
Clinical Trial Exclusion	Patients with a history of recent significant cardiovascular events (e.g., myocardial infarction, stroke) or a history of seizures were excluded from pivotal clinical studies.

---

Connection to the overall eligibility profile: Regulatory documents define eligibility for Erleada by limiting use primarily to adult males with specific prostate cancer diagnoses. The profile establishes absolute prohibitions (contraindications) for females and pregnancy and places explicit limitations or cautions on patients with severe organ function impairment or specific pre-existing clinical conditions, reflecting regulatory decisions on the patient groups for whom the drug is permitted or restricted.

Interactions with other medicines and products

The official regulatory profile for Apalutamide (Erleada) indicates that it has a high potential for drug interactions, primarily due to its role as a strong inducer of metabolic enzymes and transporters. This typically results in reduced exposure for many co-administered medicines, which may lead to a loss of their therapeutic activity.

Documented Pharmacokinetic Interactions

Substance Category	Interaction Mechanism (Regulatory Basis)	Official Outcome (Example)
Sensitive Substrates of CYP3A4, CYP2C19, CYP2C9	Strong inducer of CYP3A4 and CYP2C19; weak inducer of CYP2C9.	Decreased exposure (AUC) of substrates like Midazolam or Omeprazole.
P-gp, BCRP, OATP1B1 Substrates	Weak inducer of drug transporters.	Lower systemic exposure to substrates like Rosuvastatin or Fexofenadine.
Strong CYP2C8 Inhibitors	Inhibits Apalutamide's metabolism.	Increases Apalutamide exposure (AUC) significantly (e.g., with Gemfibrozil).

Pharmacodynamic and Procedural Constraints

Official documents indicate specific procedural constraints for certain co-administrations. Co-administration with Warfarin and coumarin-like anticoagulants requires additional International Normalised Ratio (INR) monitoring due to the potential for reduced anticoagulant effect. For women who are or may become pregnant, the combination is contraindicated due to the risk of fetal harm. Administration of Apalutamide is permitted with or without food.

Targeted Androgen Receptor (AR) Blockade

Erleada (apalutamide) is classified as a non-steroidal androgen receptor (AR) inhibitor. It functions by binding directly and with high affinity to the ligand-binding domain of the AR protein inside the cell. This interaction prevents the receptor from becoming activated by circulating androgens.

Inhibition of the Molecular Cascade

By occupying the receptor, the drug interferes with the intracellular signaling sequence at multiple distinct steps. Specifically, it inhibits the translocation of the AR from the cytoplasm into the nucleus. Furthermore, it prevents the activated AR complex from binding to specific DNA response elements. This modifies early molecular steps within the intracellular pathway, influencing the dominant signaling pattern.

Modulation of Gene Expression and Cell Activity

The complete blockade of AR nuclear activity and DNA binding leads to the impeding of AR-mediated transcription. This is the final consequence of the mechanism, resulting in the suppression of genes that promote cell survival and growth. By influencing activity within targeted pathways, the mechanism results in reduced cell proliferation and altered physiological responses that define the drug's effect profile.

The use of Erleada (apalutamide) must be precisely as directed by a healthcare provider. Apalutamide is an androgen receptor inhibitor and is typically used in conjunction with a gonadotropin-releasing hormone (GnRH) analog, unless the patient has had a prior bilateral orchiectomy.

Recommended Administration

The recommended dosage for Erleada is 240 mg taken orally once daily. This dose may be administered as one 240 mg tablet or four 60 mg tablets. Key administration points include:

• Timing: Take the dose at approximately the same time each day.
• Food: The medication may be taken with or without food.
• Method: Tablets should be swallowed whole; they must not be crushed, split, or chewed.

Missed Dose and Dosage Modification

If a dose is missed, it should be taken as soon as it is remembered on the same day. However, if an entire day has passed, the missed dose should be skipped, and the regular schedule should be resumed the following day. Do not take two doses to make up for a forgotten dose.

Dose modification may be necessary if a patient experiences a severe side effect (Grade 3 or greater toxicity). Dosing may be temporarily withheld and then resumed at the same or a reduced dose (e.g., 180 mg or 120 mg) once symptoms improve, as determined by the prescribing physician.

Research Evidence / Overview of Studies for Erleada

---

Evidence for use in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Research into Erleada for this condition, where the cancer has not spread but is no longer controlled by standard hormone therapy, primarily comes from a large, randomized clinical study called SPARTAN. This study looked at men who were at a higher risk of their cancer spreading. The primary goal of the study was to explore patterns related to the time until the cancer was observed to spread to other parts of the body.

The findings from this main research study suggest that research found an association with patterns related to the time until the cancer was observed to spread or until death occurred, when compared to standard hormone therapy alone. Later updates to the study also examined data collected regarding how long patients lived. Patient-reported outcomes describing perceived discomfort and physical well-being were also used in the study to track how symptoms evolved in the observed population.

---

Evidence for use in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

For this indication, where the cancer has spread but still responds to hormone therapy, the evidence is largely based on a major, randomized clinical study known as TITAN. This research examined Erleada in combination with standard hormone therapy, enrolling a broad group of patients including those with both high-volume and low-volume metastatic disease.

The data from the TITAN study suggest patterns related to differences in the risk of death when Erleada was added to standard hormone therapy, compared to hormone therapy alone. Studies also explored outcomes reflecting daily functioning and activity level, and the findings indicate that, in the observed patient population, health-related quality of life outcomes were similar over time, even with the addition of Erleada. Research highlights changes measured during the study period, such as how PSA levels changed over the defined study intervals, with differences in PSA changes observed in the population receiving Erleada.

---

Long-term Studies and Follow-up

The original studies for both the nmCRPC and mCSPC indications have been followed for extended durations, providing valuable long-term data. These follow-up durations were essential for gathering information about the durability of the observed response patterns and long-term outcomes for how long patients lived.

---

What is Still Uncertain about Erleada

While the research contributes significantly to the broader evidence landscape, certain areas still require more study to fully understand the treatment's profile.

One area of uncertainty relates to the long-term effects beyond the period of the main clinical trials, particularly for outcomes related to cardiovascular and bone health. Another gap is the lack of head-to-head comparative evidence against some other treatments for both indications. Finally, real-world data are still emerging to fully reflect the diversity and complexity of all patients seen in routine practice settings, and results apply only to the populations studied.

Common questions about Erleada (FAQ)

---

Q: How long will I have to take Erleada?

Official information indicates that the decision to continue treatment is generally based on disease status and the management of any experienced side effects. For example, in the main clinical trial for metastatic castration-sensitive prostate cancer, the median duration of treatment for patients was approximately 39 months.

Q: Does Erleada interact with common supplements like vitamin C or saw palmetto?

Regulatory documents state that Erleada (apalutamide) has the potential to interact with many different types of medicines and products due to its effect on certain metabolic enzymes. It is important to review all medicines and supplements, including vitamins and herbal products, with a healthcare provider before beginning treatment.

Q: Where should I store Erleada tablets at home?

According to the official product information, Erleada tablets must be stored in their original container at what is defined as Controlled Room Temperature, which is between 68 F to 77 F (20 C to 25 C). The product label specifies that the bottle must be kept tightly closed and protected from light and moisture.

Q: Will taking Erleada make me impotent or cause sexual side effects?

Official information indicates that sexual side effects have been reported as common adverse reactions during clinical trials for Erleada. These may include a decrease in a patient's sexual interest (libido) or sexual ability. Any concerns regarding side effects are typically managed in consultation with a prescribing physician.

Q: How do I know if Erleada is working for me?

Clinical trials measured the effectiveness of Erleada based on specific outcomes, such as the time it took for the cancer to spread, overall survival, and changes in prostate-specific antigen (PSA) levels. Response to treatment is typically monitored by a healthcare provider using various clinical assessments, including regular laboratory tests.

How to Store and Dispose of Erleada

Erleada (apalutamide) must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions [1]. The tablets must remain in the original container to protect them from light and moisture [1, 3]. The desiccant packet must not be removed, and the bottle should be kept out of the reach of children [1].

Stability and Disposal

If the tablet is dispersed for alternate administration, the mixture must be swallowed immediately and not stored [4]. Unused or expired Erleada should not be flushed down the toilet [5]. Disposal should be managed through an official drug take-back program [6]. If a program is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and then discarded with household trash [6].